Hanwha Solutions is pushing for the construction of a new, large-scale solar panel plant in the United States. The company wants to solidify its position as the No. 1 player in the U.S. solar module market, which is expected to expand following the passage of the Inflation Reduction Act. Hanwha Q CE
The authors are analysts of NH Investment & Securities. They can be reached at ys.jung@nhqv.com. -- Ed. To handle the current energy crisis, Europe is reviewing the continuation of NPP operations. If today’s energy woes sustain over the mid/long term, shifts in energy policy are highly likely.Operat
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. Decent 2Q22 earnings with removal of QA delay issuesSK Bioscience posted standalone sales of KRW138.3bn (-4.4% YoY) and operating profit of KRW61.2bn (-7.5% Yo
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Recommend BUY, target price of KRW380,000 We recommend BUY and TP of KRW380,000 on Hanmi Pharm. We highlight the 2Q22 earnings surprise, steady 2H22 growth forecasts for Korea/China, the release schedule of cl
As subcontract workers’ strike at Daewoo Shipbuilding & Marine Engineering (DSME) continues for nearly 50 days, the nation's other shipbuilders including Hyundai Heavy Industries are keeping a close eye on the development of the situation.On July 20, Hyundai Heavy Industries Group called a meeti
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 2Q22 sales of W316.5bn and OP of W29.6bn, with OP coming in slightly below our estimate. Beijing Hanmi led consolidated OP growth, booking OP of W17.1bn. The strength
The U.S. Food and Drug Administration (FDA) will make a decision on awarding marketing approval for Rolontis, the first new biotech drug candidate of Hanmi Pharmaceutical, in September. According to the FDA’s Prescription Drug User Fee Act (PDUFA), Rolontis’ approval deadline is set at Sept. 9.The F
The Embassy of the United Arab Emirates (UAE) has set out to actively encourage Korean SMEs, non-profit organizations and high schools to apply for the Zayed Sustainability Prize.The Zayed Sustainability Award, launched in 2008, was inspired by the sustainability and humanitarian legacy of the late
The Korean Ministry of Food and Drug Safety (KMFDS) has authorized South Korea's first homegrown COVID-19 vaccine from SK bioscience.South Korea has become one of the few countries in the world to have both a domestically developed COVID-19 vaccine and a treatment.SKYCovione is a self-assembled
The birth of a Korean COVID-19 vaccine is imminent. Korean public health authorities are expected to approve SK Bioscience’s SKY Covione (candidate substance GBP510) as early as this week. If the final approval is given as expected, Korea's first and only COVID-19 vaccine will be used at vaccina
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. Decent 2Q22 earnings expected with removal of QA delay issuesSK Bioscience is expected to record sales of KRW140.4bn (-2.9% YoY) and operating profit of KRW64.
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. EULAR 2022 held both offline and online for the first time since COVID-19 outbreakWe participated in the annual European Alliance of Associations for Rheumatol
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Outstanding efficacy and safety data for Remsima SC showcased at EULAR 2022 Celltrion showcased outstanding efficacy and safety data for Remsima SC at EULAR 2022 (Jun 1-4). According to data presented, patient
Samsung Electronics Vice Chairman Lee Jae-yong is visiting Europe, including the Netherlands, from June 7 to 18. Lee will visit ASML in Veldhoven, the Netherlands, the only producer of extreme ultraviolet (EUV) exposure equipment for advanced semiconductor microfabrication processes. He visited ASML
The Financial Supervisory Service (FSS) announced on May 31 that it would set up a task force in June in order to eradicate illegal short selling, which is one of the Yoon Suk-yeol government’s national policy goals.According to the Korea Exchange, on May 31, foreign investors accounted for 84.49 pe
The Yun Suk-yeol administration is set to resume support for large-scale R&D projects related to nuclear power plants. The government will invest about 750 billion won by 2030 in innovative small module reactor (i-SMR) technology development project and a nuclear power plant decommissioning technolo
Samsung Electronics will implement a new personnel management system starting this month, including a senior track system that allows highly skilled employees to work for the company after their retirement.The company announced on its internal bulletin board on May 10 that the new personnel manageme
Samsung Electronics Co. has released a white paper that lays out the company’s vision for securing global frequency bands for 6G, the next generation communications technology. The paper, titled “6G Spectrum: Expanding the Frontier,” discusses ways to obtain the spectrum needed to achieve the compan
Daewoo Engineering and Construction (Daewoo E&C) announced on May 5 that it will re-enter the U.S. construction market in earnest based on synergies with Jungheung Group, its parent company.From April 30 to May 9, Jungheung and Daewoo E&C executives, including Jungheung vice chairman Jung Won-joo, v
The K-mRNA Consortium, launched in June last year, is failing due to clinical trial delays and members’ move to go alone.Hanmi Pharmaceutical and GC Pharma are expanding their own mRNA business these days. Specifically, the former is planning to invest 10 billion won in drug substance manufacturing